Thiazolidinediones as anti-cancer agents

Area of Science:

• Pharmacology
• Oncology
• Endocrinology

Background:

• Thiazolidinediones (TZDs) are a class of drugs primarily used to manage type-2 diabetes by improving insulin sensitivity.
• Emerging evidence suggests TZDs possess significant anti-tumor properties, demonstrated in various in vitro and in vivo cancer models.
• The anti-cancer mechanisms of TZDs are multifaceted, involving apoptosis induction, cell cycle arrest, and cellular differentiation.

Purpose of the Study:

• To review the efficacy of thiazolidinediones (TZDs) as anti-cancer agents across common malignancies.
• To elucidate the distinct PPAR-gamma (PPAR-γ)-dependent and -independent pathways mediating TZD's anti-tumor effects.
• To explore TZD applications in lung, breast, and colon cancer therapy.

Main Methods:

• Literature review of preclinical and clinical studies on TZDs in cancer.
• Analysis of reported mechanisms of action, distinguishing PPAR-γ-dependent and -independent effects.
• Focus on studies involving lung, breast, and colon cancer models.

Main Results:

• TZDs demonstrate tumor-suppressive capabilities in various cancer types, including lung, breast, and colon cancer.
• Key anti-cancer effects include the induction of apoptosis and cell cycle arrest.
• Significant anti-tumor activity has been observed that is independent of PPAR-γ activation.

Conclusions:

• Thiazolidinediones (TZDs) represent a promising therapeutic strategy for cancer treatment, offering both PPAR-γ-dependent and -independent mechanisms.
• Further research into TZD's non-genomic and genomic effects could unlock novel anti-cancer therapies.
• The distinct anti-tumor actions warrant continued investigation for diverse oncological applications.